AbbVie drops Caribou partnership on gene-edited CAR-T therapy
AbbVie has terminated its collaboration with Caribou Biosciences to develop two off-the-shelf CAR-T therapies, Caribou disclosed Tuesday afternoon.
AbbVie paid the Jennifer Doudna-founded startup $40 million upfront in 2021, and promised up to $300 million for two CAR-T therapies with undisclosed targets. Caribou uses a hybrid gene editing technology it calls chRDNA (pronounced “chardonnay”) to engineer donor cells into CAR-T therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.